28th Conference on Retroviruses and Opportunistic Infections (CROI 2021)
For many people, CROI 2021 this anniversary marks the first recognition of the potential global risk from COVID-19: the start of a difficult year, unimaginable before.
A year ago, as delegates were either arriving in Boston or preparing to fly, CROI rapidly adapted a few days before the meeting was due to start, to become the first large virtual conference.
This year CROI was planned as a fully virtual meeting, and included approximately 3500 registered delegates.
The programme was exciting as it always is, with a significant and appropriate focus on COVID-19, including first presentations for new treatments. It also included important presentations on new and pipeline HIV drugs for both prevention and treatment, many using long-acting formulations.
The virtual meeting retained the regular CROI format and included the options to discuss presentations using chat and Q&A options to ask questions about oral presentations in real time.
One advance – a good one – is a new format for the posters. Rather than 1000+ posters, available as PDF files, the virtual meeting has edited posters to around six summary slides with a 4-minute narrative by the presenter (now called a ‘science spotlight’). Each virtual poster also allows an online dialogue with the presenter that remains online for general viewing and is a pretty good way to retain something of the direct dialogue that we
Another change though was more difficult was suggesting that a 6-month pay wall before the presentations become open access. CROI has always developed a leading role in democratising access to the latest medical research and at the start of the conference even the abstract book was planned to need a paid subscription. This is disappointing and will hopefully be rethought.
At least one community sign on letter with more than 200 organisations and individuals has already asked for the whole meeting to have a much shorter window to open access. As a result, the abstract book is now available:
Currently, content on the main conference website is only accessible to delegates, although this decision might be reviewed.
Even if all links are not yet active to non-delegates, i-Base reports will still include hyperlinks to the abstract, webinars and full presentations. We apologise for this and hope CROI reconsiders their decision after the meeting.
Reports in HTB will also therefore focus on shorter articles to emphasise summary conclusions, with comment, as a way to cover a wider range of presentations.
Early reports will be added to this page as they become available.
- CROI 2021: First results against MDR HIV using capsid inhibitor lenacapavir: potential for six-monthly ART and PrEP
- CROI 2021: Community call highlights CROI 6-month pay wall rather than usual open access
- CROI 2021: Once-daily GSK254 maturation inhibitor as treatment for HIV multidrug resistance
- CROI 2021: Dolutegravir with recycled tenofovir and lamivudine performs well second-line: primary results from the NADIA trial
- CROI 2021: Islatravir dosing for once-monthly and annual PrEP: if effective this could end HIV
- CROI 2021: Dosing for once-weekly oral ART: islatravir plus MK-8507 studies due to start in 2021
- CROI 2021: Urgency of global access to vaccines, the potential of mAbs and the lessons learned from HIV
- CROI 2021: HIV capsid uncoats in the CD4 nucleus rather than the cytoplasm – viral lifecycle updated…
This article was first posted on 6 March and is updated as information becomes available.